Record Display for the EPA National Library Catalog
RECORD NUMBER: 3 OF 11
|OLS Field Name||OLS Field Data|
|Main Title||Economic analysis of final effluent limitations guidelines and standards for the pharmaceutical manufacturing industry.|
|CORP Author||Environmental Protection Agency, Washington, DC. Office of Water.|
|Publisher||U.S. Environmental Protection Agency,|
|Report Number||EPA 821-B-98-009|
|Subjects||Pharmaceutical industry--Waste disposal--Economic aspects--United States. ; Effluent quality--Economic aspects--United States.|
|Additional Subjects||Drug industry ; Economic analysis ; Water pollution standards ; Water pollution control ; Standards compliance ; Chemical effluents ; Pollution regulations ; Facilities management ; Economic impact ; Water pollution economics ; Costs ; Cost benefit analysis ; Profits ; Market analysis ; International trade ; Social impact ; Equity(Law) ; Administrative procedures ; Air pollution control ; Guidelines ; Pharmaceutical manufacturing ; Regulatory flexibility analysis ; MACT(Maximum Achievable Control Technology)|
|Collation||1 v. (various pagings) : ill. ; 28 cm.|
This economic analysis (EA) examines compliance costs and economic impacts resulting from the U.S. Environmental Protection Agency's (EPA's) Final Effluent Limitations Guidelines and Standards for the Pharmaceutical Manufacturing Industry Point Source Category. It also investigates the costs and impacts associated with an air rule requiring Maximum Achievable Control Technology (MACT) to control air emissions, both separately and together with the Final Pharmaceutical Industry Effluent Guidelines. The EA estimates the economic effects of compliance with both final rules in terms of total aggregate annualized costs of compliance, facility closures, impacts on firms (likelihood of bankruptcy and effects on profit margins), and impacts on new sources. The EA also investigates secondary impacts on employment and communities, foreign trade, specific demographic groups, and environmental justice. This report includes a Final Regulatory Flexibility Analysis (FRFA) detailing the impacts on small businesses within the pharmaceutical industry to meet the requirements of the Regulatory Flexibility Act (RFA), as amended by the Small Business Regulatory Enforcement Fairness Act (SBREFA). Finally, the EA presents a cost-benefit analysis to meet the requirements of Executive Order 12866 and the Unfunded Mandates Reform Act.
"Office of Water"--Cover. "July 1998"--Cover. Includes bibliographical references. "EPA 821-B-98-009"--Cover.